Overview

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Status:
Completed
Trial end date:
2004-05-17
Target enrollment:
Participant gender:
Summary
This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Treatments:
Abacavir
Dideoxynucleosides
Lamivudine